Dr. Lillian Guenther

Dr. Lillian Guenther's institution, located at 262 Danny Thomas Place in Memphis, Tennessee, is dedicated to researching and treating challenging cancers, with a specific focus on osteosarcoma, the most common malignant bone tumor in children. The laboratory at this institution examines the genetic drivers behind osteosarcoma using genome-scale screening techniques and diverse models. Dr. Guenther and her team are investigating new combination approaches to treatment based on their understanding of osteosarcoma's genetic landscape. Their goal is to uncover highly effective therapeutic strategies for children with this aggressive disease.

The Guenther Lab Team consists of individuals performing clinical trials work in sarcomas and solid tumors, with a strong focus on understanding the complex genome of osteosarcoma. Dr. Guenther's research uses genome-scale CRISPR screening to examine critical non-mutated genes in the osteosarcoma cancer genome, with a specific focus on the DNA damage response cascade. By investigating promising osteosarcoma dependency genes, including those involved in DNA damage repair, Dr. Guenther aims to find ways to harness cancer cell vulnerabilities that will transform osteosarcoma treatment.

The institution's research also includes preclinical validation of potential targets for osteosarcoma treatment, such as a helicase enzyme involved in replication stress response. The laboratory is working on validating these findings in murine models and patient-derived xenografts, with the goal of identifying novel combination strategies that may lead to clinical trials. Overall, Dr. Lillian Guenther's institution is at the forefront of research in osteosarcoma treatment, with a focus on uncovering new therapeutic approaches for this challenging cancer.